FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Nadia Eckert

Senior Director - R&D Ricoh Biosciences

Wednesday 4th February 2026

Decision-Grade Alzheimer’s Biology: Enhancing Translational Confidence with Biomarker-Driven Alzheimer’s iPSC Panels

2:00 pm

Building Decision-Grade Preclinical Models: Leverage diverse patient-derived iPSC panels to capture Alzheimer’s heterogeneity
Precise, biomarker-driven patient response stratification: Enables robust identification of biomarkers and supports patient stratification into responder, moderate, and non-responder groups
De-risk pipeline decisions with human iPSC-powered predictive modeling: Embed patient-relevant biology and high-resolution biomarker analytics into preclinical workflows to confidently prioritize assets with the highest translational potential